Pulmatrix Gets $30M And An NIH Grant To Develop A Broad-Spectrum Anti-Infective
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech's technology uses two mechanisms of action to prevent infection and keep pathogens from entering the lungs.
You may also be interested in...
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
Aporkalypse Next: Pulmatrix Moves Broad-Spectrum Inhaled Anti-Infective Into Phase II
Privately held biotech believes its approach will improve on flu vaccines by enhancing the body’s own defenses to fight off a variety of pathogens.